Martin Babler
Director/Board Member chez OMEGA ALPHA SPAC
Fortune : - $ au 31/03/2024
Profil
Martin Babler is currently the Chairman, President & Chief Executive Officer at Alumis, Inc. He is also a Director at the Biotechnology Innovation Organization, an Independent Director at Prelude Therapeutics, Inc., an Independent Director at Omega Alpha SPAC, a Director at Sardona Therapeutics, Inc., and an Independent Director at 89bio, Inc. In the past, Mr. Babler served as the President & Chief Executive Officer at Talima Therapeutics, Inc. from 2010 to 2011.
He was also the President, Chief Executive Officer & Director at Principia Biopharma, Inc. from 2019 to 2020.
Additionally, he served as an Independent Director at ZS Pharma, Inc. in 2015 and at Infinity Pharmaceuticals, Inc. from 2011 to 2014.
He was a Vice President-Immunology Sales & Marketing at Genentech, Inc. from 2006 to 2007 and a Principal at Eli Lilly & Co. from 1991 to 1998.
Mr. Babler obtained his undergraduate degree from the Swiss Federal Institute of Technology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 16/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Martin Babler
| Sociétés | Poste | Début |
|---|---|---|
| OMEGA ALPHA SPAC | Director/Board Member | 01/09/2020 |
| PRELUDE THERAPEUTICS INCORPORATED | Director/Board Member | 19/07/2021 |
| 89BIO, INC. | Director/Board Member | 13/04/2024 |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Director/Board Member | - |
Alumis, Inc.
 Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a precision medicines company called Esker that aims to provide personalized treatments for people with autoimmune diseases. The company is based in San Francisco, CA. Esker uses a precision analytics platform, powered by foresite labs, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology to create medicines that change the lives of people with autoimmune disease. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021. | Chief Executive Officer | 23/09/2021 |
| Sardona Therapeutics, Inc. | Director/Board Member | - |
Anciens postes connus de Martin Babler
| Sociétés | Poste | Fin |
|---|---|---|
| PRINCIPIA BIOPHARMA INC. | Chief Executive Officer | 01/10/2020 |
| ZS PHARMA INC | Director/Board Member | 17/12/2015 |
| INFINITY PHARMACEUTICALS, INC. | Director/Board Member | 06/03/2014 |
| ░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░ ░ ░░░░░░░░░ | ░░░░░░░░░░ |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
| 89BIO, INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Talima Therapeutics, Inc.
 Talima Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talima Therapeutics, Inc. operated as a drug delivery company. It had developed a micro implant delivery technology for the localized application of small molecule drugs. The firm’s product was in phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the toenails. The company was founded in 2004 and was headquartered in San Carlos, CA. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
ZS Pharma, Inc.
 ZS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZS Pharma, Inc. engages in the development of development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. It develops treatment of hyperkalemia. It also focuses on clinical development, novel technology, and clinical trials. The company was founded by Alvaro F. Guillem and Donald Jeffrey Keyser on February 5, 2008 and is headquartered in San Mateo, CA. | Health Technology |
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
Omega Alpha SPAC
 Omega Alpha SPAC Financial ConglomeratesFinance Omega Alpha SPAC is a blank check company. Its purposes effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Otello Stampacchia, Michelle Doig, Francesco Draetta and Vincent Ossipow on October 26, 2020 and is headquartered in Boston, MA. | Finance |
Alumis, Inc.
Alumis, Inc. Pharmaceuticals: MajorHealth Technology Alumis, Inc. is a precision medicines company called Esker that aims to provide personalized treatments for people with autoimmune diseases. The company is based in San Francisco, CA. Esker uses a precision analytics platform, powered by foresite labs, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology to create medicines that change the lives of people with autoimmune disease. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021. | Health Technology |
| Sardona Therapeutics, Inc. |
